This article was originally published in The Gray Sheet
Executive SummaryApogent Technologies' Applied Biotech division will consolidate production of Forefront Diagnostics' rapid drugs-of-abuse test kits into its San Diego rapid test manufacturing facility following acquisition of Forefront, announced Nov. 20. Forefront will add about $14 mil. to Apogent sales over the next 12 months. Portsmouth, New Hampshire-based Apogent, which makes clinical diagnostics, labware and life sciences equipment, generated sales in fiscal 2001 (ended Sept. 30) of $984.5 mil., up 14%...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.